The quick-fire pace of biotech IPOs in Paris is set to continue. Inner ear disease specialist Sensorion is the latest to set terms for an IPO that will see it join Cerenis Therapeutics, Ose Pharma and Poxel in a Parisian class of 2015 that has already almost swelled to the size of last year’s crop.
Fast-growing R&D services outfit WuXi PharmaTech is marching ahead with plans to wrap a $250 million venture fund aimed at U.S. and China life sciences companies. WuXi filed documents with the SEC last week outlining the goal for WuXi Healthcare Ventures Fund II, which it’s already made a $50 million anchor investment in. …read more […]